Overview

A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cisplatin
Pemetrexed
Criteria
Inclusion Criteria:

- Measurable disease with diagnosis of Small Cell Lung Cancer.

- Performance status of 0 to 1 on the Eastern Cooperative Oncology Group performance
status schedule.

- Patients must be at least 18 years of age and have at least a 12-week life expectancy.

- No prior chemotherapy and/or prior thoracic radiotherapy.

- Adequate pulmonary function and organ function.

Exclusion Criteria:

- Patients with myocardial infarction within the preceding six months.

- Diagnosis of a serious concomitant systemic disorder.

- Prior radiotherapy to the lower neck or abdominal region.

- Significant weight loss.

- Concurrent administration of any other antitumor therapy.